ORIC — ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals Q4 2021 Earnings Call Summary

1. Key Financial Results and Metrics

• Operating Expenses: Q4 2021 operating expenses totaled $22.8 million, leading to a net loss of $22.8 million. For the full year, operating expenses were $78.9 million, resulting in a net loss of $78.7 million.
• Cash Position: As of December 31, 2021, ORIC had $280.4 million in cash and investments, extending its cash runway into the second half of 2024 following the discontinuation of ORIC-101.

2. Strategic Updates and Business Highlights

• Discontinuation of ORIC-101: The company decided to halt the development of ORIC-101 due to insufficient efficacy signals in clinical trials aimed at overcoming resistance to chemotherapy and AR modulators in prostate cancer.
• Pipeline Development: ORIC filed three INDs for new clinical programs: ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2 cancers), and ORIC-944 (prostate cancer), with initial data expected in the first half of 2023. Additionally, a new PLK4 program was introduced, targeting synthetic lethality in breast cancer.
• Clinical Trials: The trials for ORIC-101 showed no sufficient clinical benefit in both prostate cancer and advanced solid tumors, leading to the decision to discontinue.

3. Forward Guidance and Outlook

• Upcoming Data: Initial data from ORIC-533, ORIC-114, and ORIC-944 is expected in the first half of 2023.
• Cash Runway: The cash runway is now projected to last until the second half of 2024, allowing for continued investment in the pipeline despite the setback with ORIC-101.

4. Bad News, Challenges, or Points of Concern

• Discontinuation of ORIC-101: The decision to stop the development of ORIC-101 due to lack of efficacy is a significant setback, reflecting challenges in demonstrating clinical benefit in a difficult patient population.
• Clinical Trial Results: The trials for ORIC-101 revealed that despite achieving target engagement, the expected clinical outcomes were not met, raising concerns about the effectiveness of the glucocorticoid receptor inhibition approach in the studied populations.
• Market Competition: The company faces competitive pressures from other therapies in development, particularly in the oncology space, which could impact the success of its pipeline.

5. Notable Q&A Insights

• Mechanistic Insights: Questions regarding the lack of benefit from ORIC-101 highlighted potential issues with tumor heterogeneity and the emergence of alternative resistance mechanisms during treatment.
• Comparison with Competitors: The management noted differences in patient populations and treatment regimens compared to competitor studies, suggesting that the outcomes of ORIC-101 could not be directly compared with those of other therapies.
• Future Strategies: Discussions indicated a commitment to exploring combination therapies for ORIC-533 in myeloma and emphasized the importance of understanding resistance mechanisms for future trials.

Overall, while ORIC Pharmaceuticals faced a significant challenge with the discontinuation of ORIC-101, the company remains focused on advancing its robust pipeline and addressing high unmet needs in cancer treatment.